<DOC>
	<DOCNO>NCT03092206</DOCNO>
	<brief_summary>Investigation possible change insulin sensitivity healthy volunteer take follow HIV treatment combination : F/TAF ( group 1 ) compare E/C/F/TAF ( group 2 ) compare R/F/TAF ( group 3 ) . The measurement insulin sensitivity perform 30 HIV-negative healthy non-obese ( BMI 18-25 ) male volunteer 14±2 day treatment . The volunteer randomly assign one three group . Changes insulin sensitivity measure golden standard hyperinsulinemic euglycemic clamp ( HEGC ) technique , use glucose insulin infusion diagnostic agent</brief_summary>
	<brief_title>Changes Insulin Sensitivity Healthy Volunteers Taking Tenofovir Alafenamide ( TAF ) -Containing Antiretroviral Medication</brief_title>
	<detailed_description>Nearly immediately follow characterization HIV , metabolic disturbance HIV-positive patient , particularly change insulin sensitivity , report . The chronic inflammation due metabolic change cause HIV-Infection one hand antiretroviral therapy ( ART ) hand consider major contributor pathological change insulin sensitivity HIV-positive patient . There two possible mechanism discuss literature : Direct effect insulin-associated cellular glucose uptake indirect effect change lipid metabolism , i.e . lipotoxicity . Particularly , thymidine analogue , nucleoside reverse transcriptase inhibitor ( NRTI ) strongly link lipotoxicity depletion mitochondric DNA , cause insulin resistance ( IR ) HIV-positive patient healthy volunteer , ultimately result overt diabetes mellitus . Furthermore , protease inhibitor ( PI ) show lipotoxicity , increase insulin resistance . The incidence insulin resistance , ultimately , diabetes mellitus patient receive ART increase time , significantly contribute cardiovascular morbidity mortality HIV-positive patient . Due significant increase life expectation duration ART HIV-patients , early recognition unfavorable metabolic change ( i. e. insulin resistance ) gain importance . Particularly , consideration long-term toxicity safety ART receive attention . Unfortunately , appropriate strategy screen , surveillance therapeutic consequence well establish HIV-positive patient . While well establish HIV nucleoside reverse transcriptase inhibitor Tenofovir disaproxil fumarate ( TDF ) associate favorable influence lipid know negative effect insulin sensitivity , new drug Tenofovir alafenamide ( TAF ) analyze concern change insulin sensitivity yet . As TAF recently submit approval FDA EMEA treatment HIV-positive patient , widespread use potential replacement TDF expect soon . Fixed dose combination Emtricitabine ( F/TAF ) cobicistat-boosted elvitegravir ( E/C/F/TAF ) rilpivirine ( R/F/TAF ) develop take part ART setting . Unfortunately , limited data exists metabolic effect TAF TAF-containing fix dose combination drug , particularly concern change lipid metabolism insulin sensitivity HIV-positive patient healthy volunteer . For provide safety data concern change insulin sensitivity associate effect lipid data provide . We intend investigate possible change insulin sensitivity , measure described `` hyperinsulinemic eugylcemic clamp '' healthy volunteer take TAF/FTC ( group 1 ) compare E/C/F/TAF ( group 2 ) compare R/F/TAF ( group 3 ) . To best knowledge , currently data available investigating change insulin sensitivity TAF-containing ART-regiments .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male , healthy volunteer , age range ≥1840 year Written inform consent willingness attend study visit Willingness take study medication study period Birth control study period Participation interventional clinical trial and/or participation another clinical trial medicinal product within last 4 week Known allergy contraindication study medication Known metabolic dysfunction , e.g . Hypertriglyceridemia Diabetes mellitus Smoking alcohol abuse ( &gt; 15g/day alcohol consumption ) Documented HIVinfection BMI &lt; 18 &gt; 25 Recurrent medication antiretroviral medication within last 30 day ALT , AST , Bilirubin , Creatinine , TSH , blood pressure , heart rate , QTc normal range Normal range clinical chemistry define local laboratory . For blood pressure normal range define 100/60140/90 ; heart rate 60100 Known liver , kidney , heart , pulmonary , gastrointestinal , endocrinological , rheumathoid , neurological , psychiatric metabolic diseases Any situation sponsor see relevant contraindication study participation Imprisoned situate people</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>